TriangleHEALTH PROFESSIONAL · SOURCE READING
Octreotide with or without prednisone
Source: Thymoma and Thymic Carcinoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: October 25, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Evidence (octreotide with or without prednisone):
In one study, six of 16 patients achieved objective responses to octreotide (1.5 mg every day subcutaneously) associated with prednisone (0.6 mg/kg every day orally for 3 months, 0.2 mg/kg every day orally during follow-up).[3]
Source links and citations
In a study of octreotide with or without prednisone, two complete responses (5.3%) and ten partial responses (25%) were observed among 42 patients.[5]
Source links and citations
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice